La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Liechtensteinische a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Liechtensteinische..

Liechtensteinische (OTC:LLAZF) Azioni, Catena delle Opzioni

Liechtensteinische Landesbank AG is a universal banking and financial services group. The bank's business activities are divided into the following segments: Retail & Corporate Banking and International Wealth Management. The company's product and services portfolio includes various financial services, such as payment processing, lending, mortgage, individual pension fund solutions, wealth planning, taxation, asset management, and investment advisory, among others. The company generates a majority of its revenue from the Retail & Corporate Banking segment and more than half of its revenue is earned in Liechtenstein and the rest from Switzerland and Austria.

LIECHTENSTEINISCHE LANDBK by Liechtensteinische Landesbank Ag Vaduz

Liechtensteinische Landesbank AG

WIIM

AAOI

AEVA

ANET

COHR

DELL

DOCN

FCUV

MASS

NTAP

PCLA

RCAT

SMCI

TTMI

Shares of companies within the broader tech sector are trading higher amid overall market strength due to a rise in NVIDIA, a slight improvement in consumer confidence and as traders await details on potential US trade deals.

BILL

CLSK

Core Scientific, Inc. - Class A Common Stock

CORZ

CRNC

GREE

KARO

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

NTRP

RIOT

SAIH

Shares of software companies are trading higher amid overall market strength due to a rise in NVIDIA, a slight improvement in consumer confidence and as traders await details on potential US trade deals.

<p><a href="https://downdetector.com/status/reddit/">https://downdetector.com/status/reddit/</a></p>


News

General

RDDT

Downdetector Says User Reports Indicate Problems At Reddit

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Hims &amp; Hers Health</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HIMS, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 65 uncommon options trades for Hims &amp; Hers Health.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 55% bullish and 33%, bearish.</p>
<p>Out of all of the special options we uncovered, 12 are puts, for a total amount of $453,745, and 53 are calls, for a total amount of $3,066,660.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $1.0 to $105.0 for Hims &amp; Hers Health over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Hims &amp; Hers Health's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Hims &amp; Hers Health's whale trades within a strike price range from $1.0 to $105.0 in the last 30 days. </p>
<h3>Hims &amp; Hers Health Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977392_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$3.8</td>
<td>$3.75</td>
<td>$3.8</td>
<td>$66.00</td>
<td>$165.6K</td>
<td>1.0K</td>
<td>4.0K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$25.0</td>
<td>$24.3</td>
<td>$25.0</td>
<td>$65.00</td>
<td>$137.5K</td>
<td>189</td>
<td>65</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$25.0</td>
<td>$24.25</td>
<td>$25.0</td>
<td>$60.00</td>
<td>$125.0K</td>
<td>1.1K</td>
<td>83</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$53.65</td>
<td>$52.55</td>
<td>$53.64</td>
<td>$3.00</td>
<td>$112.6K</td>
<td>302</td>
<td>36</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.35</td>
<td>$9.7</td>
<td>$9.83</td>
<td>$58.00</td>
<td>$110.7K</td>
<td>669</td>
<td>541</td>
</tr>
</tbody>
</table>
</p>
<h3>About Hims &amp; Hers Health</h3>
<p>Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.</p>
<p>Having examined the options trading patterns of Hims &amp; Hers Health, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Hims &amp; Hers Health</h3>
<ul>
<li>Currently trading with a volume of 103,101,957, the HIMS's price is down by -2.46%, now at $55.37. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 62 days.</li>
</ul>
<h3>What The Experts Say On Hims &amp; Hers Health</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $43.33.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Citigroup persists with their Sell rating on Hims &amp; Hers Health, maintaining a target price of $30.<br />
&#x2A; In a cautious move, an analyst from Piper Sandler downgraded its rating to Neutral, setting a price target of $39.<br />
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $61. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Hims &amp; Hers Health, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Market Whales and Their Recent Bets on HIMS Options

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Microchip Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCHP, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Microchip Technology.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 64% bullish and 28%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $203,318, and 9 are calls, for a total amount of $543,287.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $77.5 for Microchip Technology, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Microchip Technology's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Microchip Technology's significant trades, within a strike price range of $55.0 to $77.5, over the past month.</p>
<h3>Microchip Technology 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977386_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$2.15</td>
<td>$2.0</td>
<td>$2.15</td>
<td>$60.00</td>
<td>$107.5K</td>
<td>366</td>
<td>763</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$2.25</td>
<td>$2.2</td>
<td>$2.2</td>
<td>$60.00</td>
<td>$72.6K</td>
<td>366</td>
<td>1.0K</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.8</td>
<td>$8.5</td>
<td>$8.5</td>
<td>$65.00</td>
<td>$68.8K</td>
<td>877</td>
<td>24</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.6</td>
<td>$1.4</td>
<td>$1.4</td>
<td>$65.00</td>
<td>$68.6K</td>
<td>1.7K</td>
<td>507</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$8.8</td>
<td>$8.7</td>
<td>$8.79</td>
<td>$55.00</td>
<td>$63.3K</td>
<td>906</td>
<td>72</td>
</tr>
</tbody>
</table>
</p>
<h3>About Microchip Technology</h3>
<p>Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.</p>
<h3>Where Is Microchip Technology Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 8,896,292, with MCHP's price up by 0.7%, positioned at $60.42.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 58 days.</li>
</ul>
<h3>Expert Opinions on Microchip Technology</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $61.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from UBS persists with their Buy rating on Microchip Technology, maintaining a target price of $65.<br />
&#x2A; An analyst from Raymond James downgraded its action to Strong Buy with a price target of $65.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Microchip Technology with a target price of $50.<br />
&#x2A; An analyst from UBS persists with their Buy rating on Microchip Technology, maintaining a target price of $60.<br />
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $66.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Microchip Technology, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


MCHP

Market Whales and Their Recent Bets on MCHP Options

<p>Financial giants have made a conspicuous bullish move on First Solar. Our analysis of options history for First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) revealed 68 unusual trades.</p>
<p>Delving into the details, we found 47% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 13 were puts, with a value of $601,706, and 55 were calls, valued at $2,661,063.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $65.0 and $270.0 for First Solar, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for First Solar's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of First Solar's whale activity within a strike price range from $65.0 to $270.0 in the last 30 days. </p>
<h3>First Solar 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977381_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$39.45</td>
<td>$39.0</td>
<td>$39.0</td>
<td>$140.00</td>
<td>$195.0K</td>
<td>391</td>
<td>51</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$39.15</td>
<td>$37.15</td>
<td>$37.85</td>
<td>$140.00</td>
<td>$177.8K</td>
<td>391</td>
<td>54</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$8.9</td>
<td>$8.85</td>
<td>$8.85</td>
<td>$90.00</td>
<td>$144.2K</td>
<td>37</td>
<td>5</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$3.6</td>
<td>$3.45</td>
<td>$3.5</td>
<td>$220.00</td>
<td>$78.2K</td>
<td>2.0K</td>
<td>2.4K</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$97.2</td>
<td>$93.85</td>
<td>$95.44</td>
<td>$65.00</td>
<td>$76.3K</td>
<td>63</td>
<td>16</td>
</tr>
</tbody>
</table>
</p>
<h3>About First Solar</h3>
<p>First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.</p>
<h3>Present Market Standing of First Solar</h3>
<ul>
<li>With a trading volume of 2,922,156, the price of FSLR is down by -0.37%, reaching $149.1.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
<h3>What Analysts Are Saying About First Solar</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $222.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for First Solar, targeting a price of $204.<br />
&#x2A; An analyst from Wolfe Research has elevated its stance to Outperform, setting a new price target at $221.<br />
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on First Solar with a target price of $157.<br />
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on First Solar with a target price of $255.<br />
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Outperform rating on First Solar with a target price of $275. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest First Solar options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


FSLR

Spotlight on First Solar: Analyzing the Surge in Options Activity

AVGO

AXTI

CRDO

CSIQ

ENPH

ENTG

INTC

NVDA

NXPI

WKEY

WOLF

Shares of semiconductor companies are trading higher amid overall market strength due to a rise in NVIDIA, a slight improvement in consumer confidence and as traders await details on potential US trade deals.

<p><strong>CrowdStrike Holdings Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are trading higher Tuesday ahead of the company's <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45745176/crowdstrike-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-3">first-quarter earnings report</a>.</p>
<p><strong>What To Know</strong>: CrowdStrike is expected to report revenue of $1.16 billion and earnings per share of 81 cents after the market closes on Tuesday. In the previous quarter, the company beat earnings estimates, but missed slightly on revenue and its share price fell 6% the following day. Investors will be paying close attention to both earnings results and forward guidance as <a href="https://www.benzinga.com/news/earnings/25/05/45658340/sentinelone-q1-earnings-revenue-beat-eps-in-line-shares-dive-on-soft-guidance">cybersecurity results</a> have been mixed over the past month. </p>
<p>Wedbush analyst Daniel Ives maintained an Outperform rating and lifted the price target from $475 to $525 on Tuesday.</p>
<p>Rosenblatt analyst <strong>Catharine Trebnick </strong>reiterated a <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45725122/crowdstrike-analyst-raises-price-target-ahead-of-q1-results-benefits-from-stable-cybersecurity-budgets-despite-macro-uncertainty">Buy rating</a> and raised the price target from $450 to $515 ahead of earnings, citing consistent demand for cybersecurity services and growing IT consolidation trends that benefit platform-based security vendors like CrowdStrike.</p>
<p>Despite macroeconomic uncertainty, security budgets have remained stable, supported by reseller feedback and industry surveys. Trebnick pointed out that companies are continuing to seek out integrated platforms to simplify operations and reduce risk exposure, which puts CrowdStrike in a favorable position.</p>
<p>The price target increase also reflects a broader expansion in valuation multiples across the cybersecurity sector, which have risen approximately 31% over the past two months. CrowdStrike's Falcon platform, which delivers cloud-native security across endpoints, workloads and identities, has positioned the company to benefit from the trend toward unified security solutions.</p>
<p>Compared to its peers, CrowdStrike leads in revenue growth and gross profit but lags in return metrics such as ROE and ROA. Still, analysts maintain an overall positive outlook, with the company currently holding an Outperform consensus rating across analyst coverage.</p>
<p><strong>CRWD Price Action:</strong> CrowdStrike shares were up 1.77% at $487.63 at the time of publication Tuesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a> CrowdStrike shares are up more than 42% year-to-date heading into Tuesday&#8217;s print.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="EXCLUSIVE: May's 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank?<br />
">EXCLUSIVE: May&#8217;s 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank?<br /></a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


Earnings

Previews

Movers

CRWD

CrowdStrike Stock Climbs To New Highs Ahead Of Q1 Earnings: What To Know

<p>Across the recent three months, 8 analysts have shared their insights on Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $69.62, a high estimate of $92.00, and a low estimate of $59.00. Observing a downward trend, the current average is 0.54% lower than the prior average price target of $70.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977277_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Incyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$73.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$59.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$67.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$72.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Incyte. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Incyte compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Incyte's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Incyte's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/INCY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Incyte analyst ratings.</strong></a></p>
<h2>Get to Know Incyte Better</h2>
<p>Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.</p>
<h3>Incyte: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Incyte's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>19.53%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Incyte's net margin excels beyond industry benchmarks, reaching <strong>15.03%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Incyte's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>4.45%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.83%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

INCY

Where Incyte Stands With Analysts

<p>In the current session, the stock is trading at $345.57, after a <strong>0.01%</strong> increase. Over the past month, <strong>Quanta Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>)</strong> stock increased by <strong>12.10%</strong>, and in the past year, by <strong>29.05%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1748977262_0.png" alt="Past Year Chart" /></p>

<h3>Quanta Services P/E Compared to Competitors</h3>
<p>The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. </p>
<p>Compared to the aggregate P/E ratio of <strong>50.47</strong> in the Construction &amp; Engineering industry, Quanta Services Inc. has a higher P/E ratio of <strong>55.73</strong>. Shareholders might be inclined to think that Quanta Services Inc. might perform better than its industry group. It's also possible that the stock is overvalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1748977262_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

A Look Into Quanta Services Inc's Price Over Earnings

<p>Ratings for NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.83, a high estimate of $8.10, and a low estimate of $3.50. Highlighting a 12.66% decrease, the current average has fallen from the previous average price target of $5.53. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977257_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of NIO by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.50</td>
<td>$4.20</td>
</tr>
<tr>
<td>Jeff Chung</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.10</td>
<td>$8.90</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.20</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NIO. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of NIO compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for NIO's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NIO's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NIO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on NIO analyst ratings.</strong></a></p>
<h2>Discovering NIO: A Closer Look</h2>
<p>Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.</p>
<h3>NIO's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> NIO's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>15.2%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> NIO's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-36.2%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> NIO's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-82.38%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> NIO's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-6.74%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>5.67</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NIO Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

<p>Across the recent three months, 5 analysts have shared their insights on Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.2, along with a high estimate of $29.00 and a low estimate of $11.00. Observing a downward trend, the current average is 15.74% lower than the prior average price target of $21.60. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977249_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Ameresco. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$11.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ameresco. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ameresco compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Ameresco's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ameresco's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AMRC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Ameresco analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>About Ameresco</h2>
<p>Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.</p>
<h3>Financial Milestones: Ameresco's Journey</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Ameresco's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>18.24%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-1.56%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-0.54%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ameresco's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-0.13%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.76</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AMRC

Analyst Expectations For Ameresco's Future

<p>Analysts' ratings for DigitalBridge Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NYSE">DBRG</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.62, a high estimate of $16.00, and a low estimate of $10.50. A 5.29% drop is evident in the current average compared to the previous average price target of $14.38. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977238_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of DigitalBridge Gr by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Miller</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.50</td>
<td>$13.50</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DigitalBridge Gr. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of DigitalBridge Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of DigitalBridge Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of DigitalBridge Gr's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DBRG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on DigitalBridge Gr analyst ratings.</strong></a></p>
<h2>About DigitalBridge Gr</h2>
<p>DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.</p>
<h3>DigitalBridge Gr: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> DigitalBridge Gr's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-38.91%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> DigitalBridge Gr's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-1.93%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> DigitalBridge Gr's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-0.08%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-0.03%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.29</strong>, DigitalBridge Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DBRG

Forecasting The Future: 4 Analyst Projections For DigitalBridge Gr

<p><strong>Ladder Capital's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LADR#NYSE">LADR</a>) short percent of float has fallen 4.62% since its last report. The company recently reported that it has <strong>1.40 million shares sold short</strong>, which is 1.24% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.81 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Ladder Capital Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977230_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Ladder Capital has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Ladder Capital's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ladder Capital's peer group average for short interest as a percentage of float is 6.80%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

LADR

What's Driving the Market Sentiment Around Ladder Capital?

<p><strong>Edison Intl's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) short percent of float has fallen 15.18% since its last report. The company recently reported that it has <strong>7.32 million shares sold short</strong>, which is 2.18% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.8 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Edison Intl Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977225_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Edison Intl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Edison Intl's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Edison Intl's peer group average for short interest as a percentage of float is 3.15%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


What Does the Market Think About Edison Intl?

<p>Across the recent three months, 5 analysts have shared their insights on Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Designer Brands, presenting an average target of $5.3, a high estimate of $6.00, and a low estimate of $4.50. Experiencing a 1.85% decline, the current average is now lower than the previous average price target of $5.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977222_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Designer Brands's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$4.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Designer Brands. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Designer Brands compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Designer Brands's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Designer Brands's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DBI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Designer Brands analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Designer Brands</h2>
<p>Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.</p>
<h3>Breaking Down Designer Brands's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Designer Brands's revenue growth over a period of 3M has faced challenges. As of 31 January, 2025, the company experienced a revenue decline of approximately <strong>-5.41%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Designer Brands's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-5.35%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Designer Brands's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-12.79%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Designer Brands's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-1.87%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>4.62</strong>, Designer Brands faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Designer Brands Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

<p><strong>Bank of New York Mellon's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) short percent of float has risen 3.67% since its last report. The company recently reported that it has <strong>8.09 million shares sold short</strong>, which is 1.13% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.11 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Bank of New York Mellon Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977220_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Bank of New York Mellon has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Bank of New York Mellon's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Bank of New York Mellon's peer group average for short interest as a percentage of float is 4.14%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into Bank of New York Mellon's Recent Short Interest

<p>During the last three months, 7 analysts shared their evaluations of Parsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Parsons and provided 12-month price targets. The average target is $80.29, accompanied by a high estimate of $110.00 and a low estimate of $65.00. This current average has decreased by 7.56% from the previous average price target of $86.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748977213_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of Parsons by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald Epstein</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Sheila Kahyaoglu</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$65.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$69.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Ronald Epstein</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Parsons. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Parsons compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Parsons's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Parsons's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PSN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Parsons analyst ratings.</strong></a></p>
<h2>About Parsons</h2>
<p>Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.</p>
<h3>Financial Insights: Parsons</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Parsons displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>1.22%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Parsons's net margin is impressive, surpassing industry averages. With a net margin of <strong>4.26%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Parsons's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.72%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Parsons's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.21%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Parsons's debt-to-equity ratio is below the industry average. With a ratio of <b>0.56</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 7 Analyst Projections For Parsons

<p>Immix Biopharma today presented results at ASCO from its U.S. multi-center <strong>NEXICART-2</strong> Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint.</p>
<p><i>– NXC-201 met primary endpoint with a complete response (CR) rate of 70% (7/10 patients) –</i></p>
<p><i>– No relapses recorded to-date; no safety signals identified –</i></p>
<p><i>– Immix plans Biologics License Application (BLA) for FDA approval –</i></p>
<p><i>– Results were presented by Heather Landau, MD, of Memorial Sloan Kettering Cancer Center –</i></p>
<p><i>– KOL event to discuss significance Tuesday, June 3, 2025 3:00pm ET after ASCO presentation: </i><a href="https://www.globenewswire.com/Tracker?data=7FXvwgLBV0akkjccOAwp9WRrZ6VqZfEGmvcwrNsFxXcfw5chDUxPMFHoiqtZfr82szRgQ4PV1dvKRJjEYz2w3rWgb2zmGoyBP19WbRbSJklTzRNAqB3VepNsfZZiTUqPRuCIiMeKlrzQfgZqqD1zdw=="><i>https://lifescievents.com/event/immix-asco</i></a><i>&nbsp;–</i></p>
<p>LOS ANGELES, CA, June 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced meeting its primary endpoint of complete response (CR) rate for cell therapy NXC-201 at an oral presentation of interim results at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The oral presentation summarized meeting its interim results endpoint in from the U.S. multi-site NEXICART-2 clinical trial evaluating NXC-201 in relapsed/refractory AL Amyloidosis with a data cutoff of April 11, 2025.</p>
<p>A Key Opinion Leader (KOL) event to discuss the significance will be held Tuesday, June 3, 2025 3:00pm ET with live Q&amp;A (register <a href="https://www.globenewswire.com/Tracker?data=ZIOf_U4fMbYSGMB17Hq1prnFvUA8D4sA-KPm0tPwHkXpShTsCUkP0Q3OBv68xbzH3W27y9m-2f1lllJx-im1SLRi9G-CKiS9sFag0xYkMPA=">here</a> to participate).</p>
<p>"Meeting primary endpoint at this interim data readout is a testament to the groundbreaking efficacy of NXC-201, as we work toward the first approval in the challenging indication of relapsed/refractory AL Amyloidosis," said Ilya Rachman, MD, PhD, Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, "This inflection point further accelerates our progress toward BLA submission for FDA approval."</p>
<p>Immix's Phase 1/2 NEXICART-2 clinical trial is a U.S. multi-site, single-arm study to evaluate the efficacy and safety of NXC-201 in patients who are refractory to, or relapse on treatment for relapsed/refractory AL Amyloidosis.</p>


Comments

Liechtensteinische

Liechtensteinische (LLAZF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO